{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:50:56Z","timestamp":1777477856871,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1A2C2004696"],"award-info":[{"award-number":["2021R1A2C2004696"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1A4A1021787"],"award-info":[{"award-number":["2021R1A4A1021787"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.cbi.2024.110903","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T02:22:40Z","timestamp":1707186160000},"page":"110903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Role of microsomal metabolism in bromfenac-induced cytotoxicity"],"prefix":"10.1016","volume":"391","author":[{"given":"Jang Su","family":"Jeon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyemin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seongyea","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7981-9892","authenticated-orcid":false,"given":"Jaehoon","family":"Sim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Kyum","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2024.110903_bib1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1056\/NEJMra1816149","article-title":"Drug-induced liver injury \u2014 types and phenotypes","volume":"381","author":"Hoofnagle","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cbi.2024.110903_bib2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/flgastro-2021-101886","article-title":"Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI)","volume":"13","author":"Brennan","year":"2022","journal-title":"Frontline Gastroenterol."},{"key":"10.1016\/j.cbi.2024.110903_bib3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/00002018-200124070-00001","article-title":"Drug-induced liver disorders: implications for drug development and regulation","volume":"24","author":"Kaplowitz","year":"2001","journal-title":"Drug Saf."},{"key":"10.1016\/j.cbi.2024.110903_bib4","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1001\/jama.287.17.2273","article-title":"Safety of newly approved drugs: implications for prescribing","volume":"287","author":"Temple","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cbi.2024.110903_bib5","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jhep.2011.02.007","article-title":"Causality assessment methods in drug induced liver injury: strengths and weaknesses","volume":"55","author":"Garcia-Cortes","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cbi.2024.110903_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"Andrade","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.cbi.2024.110903_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231163410","article-title":"Drug-induced liver injury: a comprehensive review","volume":"16","author":"Hosack","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cbi.2024.110903_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev.pharmtox.45.120403.100058","article-title":"The role of metabolic activation in drug-induced hepatotoxicity","volume":"45","author":"Park","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.cbi.2024.110903_bib9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1021\/tx600260a","article-title":"Applying mechanisms of chemical toxicity to predict drug safety","volume":"20","author":"Guengerich","year":"2007","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2024.110903_bib10","first-page":"720","article-title":"Isolation and identification of bromfenac glucoside from rat bile","volume":"26","author":"Kirkman","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2024.110903_bib11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/lt.500050607","article-title":"Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group","volume":"5","author":"Fontana","year":"1999","journal-title":"Liver Transplant. Surg."},{"key":"10.1016\/j.cbi.2024.110903_bib12","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1001\/jama.281.18.1728","article-title":"The safety of newly approved medicines: do recent market removals mean there is a problem?","volume":"281","author":"Friedman","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.cbi.2024.110903_bib13","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/j.1572-0241.1999.01093.x","article-title":"Severe hepatotoxicity associated with bromfenac sodium","volume":"94","author":"Moses","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cbi.2024.110903_bib14","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1345\/aph.18364","article-title":"Fatal fulminant hepatitis associated with bromfenac use","volume":"33","author":"Rabkin","year":"1999","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.cbi.2024.110903_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/01926230590522121","article-title":"Do preclinical testing strategies help predict human hepatotoxic potentials?","volume":"33","author":"Peters","year":"2005","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.cbi.2024.110903_bib16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1021\/tx200168d","article-title":"Structural alert\/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States","volume":"24","author":"Stepan","year":"2011","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2024.110903_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0009-2797(03)00020-6","article-title":"Acyl glucuronide reactivity in perspective: biological consequences","volume":"145","author":"Bailey","year":"2003","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cbi.2024.110903_bib18","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1124\/dmd.110.034173","article-title":"Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide","volume":"38","author":"Sawamura","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2024.110903_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.dmpk.2016.11.002","article-title":"Toxicological potential of acyl glucuronides and its assessment","volume":"32","author":"Iwamura","year":"2017","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.cbi.2024.110903_bib20","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1124\/dmd.109.028860","article-title":"Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins","volume":"37","author":"Usui","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2024.110903_bib21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1021\/acs.chemrestox.7b00293","article-title":"Role of glucuronidation and P450 oxidation in the bioactivation of bromfenac","volume":"31","author":"Driscoll","year":"2018","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2024.110903_bib22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/acs.chemrestox.9b00268","article-title":"Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac dagger","volume":"33","author":"Yadav","year":"2020","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2024.110903_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.cbi.2024.110903_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2024.110903_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10565-007-9018-x","article-title":"Development of an in vitro assay for the investigation of metabolism-induced drug hepatotoxicity","volume":"24","author":"Otto","year":"2008","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.cbi.2024.110903_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121575","article-title":"Development of human pluripotent stem cell-derived hepatic organoids as an alternative model for drug safety assessment","volume":"286","author":"Kim","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.cbi.2024.110903_bib27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/dom.12467","article-title":"Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial","volume":"17","author":"Kaku","year":"2015","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.cbi.2024.110903_bib28","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/dom.12693","article-title":"Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study","volume":"18","author":"Kaku","year":"2016","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.cbi.2024.110903_bib29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1124\/dmd.118.084889","article-title":"Characterization of fasiglifam-related liver toxicity in dogs","volume":"47","author":"Kogame","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2024.110903_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00228-006-0241-9","article-title":"Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes","volume":"63","author":"Mano","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2024.110903_bib31","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/j.1552-4604.1998.tb04815.x","article-title":"Metabolic disposition of 14C-bromfenac in healthy male volunteers","volume":"38","author":"Osman","year":"1998","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2024.110903_bib32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00003088-199936060-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of bromfenac","volume":"36","author":"Skjodt","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.cbi.2024.110903_bib33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0022-3565(25)10294-2","article-title":"Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs","volume":"264","author":"Jin","year":"1993","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.cbi.2024.110903_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/toxsci\/61.1.49","article-title":"Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac","volume":"61","author":"King","year":"2001","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.cbi.2024.110903_bib35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3109\/03602532.2014.973037","article-title":"Transcriptional regulation of human UDP-glucuronosyltransferase genes","volume":"46","author":"Hu","year":"2014","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.cbi.2024.110903_bib36","first-page":"50","article-title":"Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury","volume":"157","author":"Wolenski","year":"2017","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.cbi.2024.110903_bib37","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/toxsci\/kfx040","article-title":"Fasiglifam (TAK-875): mechanistic investigation and retrospective identification of hazards for drug induced liver injury","volume":"163","author":"Otieno","year":"2018","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.cbi.2024.110903_bib38","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/toxsci\/kfy253","article-title":"Quantitative systems toxicology analysis of in vitro mechanistic assays reveals importance of bile acid accumulation and mitochondrial dysfunction in TAK-875-induced liver injury","volume":"167","author":"Longo","year":"2019","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.cbi.2024.110903_bib39","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1021\/acs.chemrestox.9b00111","article-title":"Quantitative evaluation of reactivity and toxicity of acyl glucuronides by [35S]cysteine trapping","volume":"32","author":"Harada","year":"2019","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2024.110903_bib40","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0090-9556(25)07493-8","article-title":"Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver","volume":"24","author":"Sallustio","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2024.110903_bib41","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/S0016-5085(98)70026-5","article-title":"Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats","volume":"115","author":"Seitz","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cbi.2024.110903_bib42","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1023\/A:1007576903935","article-title":"Pharmacokinetic study of the hepatobiliary transport of indomethacin","volume":"17","author":"Kouzuki","year":"2000","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.cbi.2024.110903_bib43","series-title":"Mechanistic Toxicology: the Molecular Basis of How Chemicals Disrupt Biological Targets","author":"Boelsterli","year":"2007"},{"key":"10.1016\/j.cbi.2024.110903_bib44","series-title":"Drug-Induced Liver Disease","first-page":"369","article-title":"Chapter 22 - nonsteroidal antiinflammatory drugs and leukotriene receptor antagonists","author":"Lewis","year":"2013"},{"key":"10.1016\/j.cbi.2024.110903_bib45","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1021\/acs.molpharmaceut.5b00411","article-title":"Hepatic disposition of gemfibrozil and its major metabolite gemfibrozil 1-O-\u03b2-Glucuronide","volume":"12","author":"Kimoto","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.cbi.2024.110903_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111842","article-title":"Oxindole and its derivatives: a review on recent progress in biological activities","volume":"141","author":"Khetmalis","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cbi.2024.110903_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9071505","article-title":"Beta-lactams toxicity in the intensive care unit: an underestimated collateral damage?","volume":"9","author":"Roger","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.cbi.2024.110903_bib48","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3390\/antibiotics12050870","article-title":"Beta-lactam dose optimisation in the intensive care unit: targets, therapeutic drug monitoring and toxicity","volume":"12","author":"Legg","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.cbi.2024.110903_bib49","doi-asserted-by":"crossref","first-page":"599","DOI":"10.4062\/biomolther.2017.225","article-title":"Fasiglifam (TAK-875), a G protein-coupled receptor 40 (GPR40) agonist, may induce hepatotoxicity through reactive oxygen species generation in a GPR40-dependent manner","volume":"26","author":"Kim","year":"2018","journal-title":"Biomol Ther (Seoul)"},{"key":"10.1016\/j.cbi.2024.110903_bib50","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.apsb.2021.05.028","article-title":"Hepatotoxicity reports in the FDA adverse event reporting system database: a comparison of drugs that cause injury via mitochondrial or other mechanisms","volume":"11","author":"Rana","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.cbi.2024.110903_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2009.07.005","article-title":"Differential effects of non-steroidal anti-inflammatory drugs on mitochondrial dysfunction during oxidative stress","volume":"490","author":"Lal","year":"2009","journal-title":"Arch. Biochem. Biophys."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279724000498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279724000498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:14:08Z","timestamp":1757859248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279724000498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":51,"alternative-id":["S0009279724000498"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2024.110903","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of microsomal metabolism in bromfenac-induced cytotoxicity","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2024.110903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110903"}}